DocuSign's sterling quarter pushes its stock up 11%
By Jon Swartz
DocuSign Inc.'s stock jumped 11% higher in extended trading Thursday after the company racked up quarterly results that dusted analysts' revenue and earnings estimates, as well as offering strong revenue guidance.
The electronic-signature company (DOCU) reported fiscal fourth-quarter net income of $27.2 million, or 13 cents a share, compared with net income of $4.9 million, or 2 cents a share, in the same quarter a year ago. Adjusted earnings were 76 cents a share.
DocuSign's sales climbed 8% to $712.4 million from $659.6 million in the same quarter a year ago.
Analysts surveyed by FactSet had expected on average net income of 65 cents a share on revenue of $698 million.
DocuSign provided first-quarter sales guidance of $704 million to $708 million, while FactSet analysts are forecasting $701 million.
Shares of DocuSign have sunk 17% over the past year, while the broader S&P 500 index SPX has surged 32%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-07-24 2016ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks